The Motley Fool

Dr Martens recently went public, but is its stock a buy?

Image source: Getty Images

Iconic bootmaker Dr Martens (LSE: DOCS)’s stock hit the public markets on 2nd February when private equity firm Permira sold a 35% stake in the company. The shares were initially sold at a price of around 370p, but in the last few weeks massive investor demand has pushed the share price up by over 30% at the time of writing to 492p, giving the company a valuation just shy of £5 billion.

What’s driving this demand?

One reason Dr Martens stock is appealing to investors is the company’s strong fundamentals. In FY2020, Dr Martens grew revenues by 48%, up from 30% the previous year. EBITDA (earnings before interest, taxes, depreciation, and amortisation) has also increased by 92% annually between FY2018 and FY2020, and profits have gone from negative £5.7 million to positive £74.8 million over the same period.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Margins are good with operating and net profit margins of 21.1% and 11.1% respectively in FY2020, and the company also achieved a ROCE (return on capital employed) of 31% in the last fiscal year, indicating a high level of efficiency.

Covid-19 has demonstrated the business’ resilience, with revenues growing by 18% in the six months between March 2020 and September 2020. A large part of this has been down to investments in ecommerce in a bid to increase the direct-to-consumer side of the business, which is now responsible for 45% of sales, up from 26% in FY2015. This is likely to be a major catalyst for growth in the coming years.

The balance sheet isn’t too bad, either. As of September 2020, the company had a net debt (excluding lease liabilities) of -£269.2 million, representing a manageable 1.3 times trailing twelve-month EBITDA.

Probably the best thing Dr Martens stock has going for it, however, is its iconic brand. Its chunky, lace up boots are instantly recognisable and have a rich history of symbolising youthful rebelliousness since the 60s. Although today the boots have a wider appeal, with 11 million boots having been sold across 60 countries in FY2020, the company has maintained its exceptionally strong brand, giving Dr Martens significant pricing power and protection from competition.

Is the stock undervalued?

The recent sharp increase in share price has certainly made the company more expensive, with the shares now trading at just over 57 times trailing twelve months earnings (September 2019 – September 2020). This seems excessively high when compared to broad markets such as the FTSE 100, which is currently trading at a price-to-earnings (P/E) ratio of 17.55.

However, as mentioned, Dr Martens is growing at a very fast pace. If Dr Martens manages to maintain this pace for an extended period of time, this valuation doesn’t seem too bad. In fact, when compared to similar companies, such as Nike, which is trading at a P/E of 79.88 having grown revenues at a CAGR (compound annual growth rate) of just over 4% over the last five years, this price seems very attractive.

One thing Dr Martens does lack is a long history of profitability. But the company’s investments in ecommerce and its strong brand make me confident that it can continue to grow rapidly in the future, making Dr Martens stock a buy for my portfolio.

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Ollie Henry has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.